2 terminated, 1 withdrawn. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Withdrawn 1 |
Follow Xevinapant: new trials by email Literature Review of Xevinapant trials Research Report on Xevinapant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) Xevinapant - Recurrent High-grade Glioma | Phase 1 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2024-07-22 | 2024-12-04 | |
| Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer Xevinapant, Carboplatin, Paclitaxel - Head and Neck Cancer, Head and Neck Neoplasms | Phase 1 | Terminated | University of Chicago | 42 | 2024-01-24 | 2026-03-31 |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT) - Head and Neck Cancer | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 18 | 2024-01-18 | 2025-09-29 |
Head and Neck Neoplasms (2) · Glioma (1) · Laryngeal Diseases (1) · Squamous Cell Carcinoma of Head and Neck (1)
EMD Serono Research & Development Institute, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · University of Chicago (1)
United States (2) · Belgium (1) · Israel (1) · South Korea (1) · Spain (1) · Taiwan (1)
Ari Rosenberg, ND (1) · Arnold Etame, MD, PhD (1)
2023 (1)